ABSTRACT Amygdalin, the gentiobioside derivative of mandelonitrile commonly referred to as Laetrile, is presently under intensive investigation as a potential cancer chemotherapeutic agent. Because of this interest, we investigated the activity of (3-glucosidases that cleave glucose from amygdalin and from prunasin (mandelonitrile monoglucoside) in tissues from germ-free rats and in normal and neoplastic human tissues. Rat and human small intestinal mucosa contain high levels of activity of glucosidases that act on both of these cyanogenic glucosides. Release of glucose from these compounds was not detected in any of the human neoplastic tissues examined in the present study. These observations are consistent with reports of cyanide toxicity through the oral use of amygdalin or prunasin and pose serious questions concerning the alleged tumoricidal effect of amygdalin.
Amygdalin (D-mandelonitrile-,-D-glucosido-6-,B-D-glucoside)
has been promoted (1) and, in 23 American states, legalized as an oral chemotherapeutic agent for "terminal" cancer. These endeavors were endorsed despite documented heterogeneity of amygdalin and "Laetrile" preparations (2, 3), a dearth of evidence of the effectiveness of amygdalin on animal (4-6) and human neoplasms (7, 8) , and serious questions regarding potential cyanide toxicity.
Schmidt et al (9) demonstrated that oral administration of amygdalin in doses equivalent to the recommended human tumoricidial doses along with the sweet almond preparations containing the amygdalin-hydrolyzing enzyme complex emulsion produced high levels of HCN in serum, clinical signs ofcyanide toxicity, and death of 6 of 10 experimental animals. Khandekar and Edelman (10) administered amygdalin to rats intraperitoneally and demonstrated dose-dependent mortality and clinical evidence of cyanide toxicity without the concurrent use of almond 13-glucosidases. However, Ames et at (11) found that parenteral administration ofamygdalin resulted in excretion ofthis compound in the urine primarily in an unchanged form. In humans, Moertel et at (12) found that intravenous infusion of amygdalin produced neither cyanidemia nor signs oftoxicity but that oral administration resulted in significant blood cyanide levels and that, in one case, oral amygdalin plus almond extract produced transient symptoms of cyanide intoxiciation and further increase ofblood cyanide. These studies seemed to indicate that amygdalin was probably metabolized in some portion(s) of the gastrointestinal tract.
Freese et at (13) isolated and partially purified a neutral (3(1-*6)-glucosidase that catalyzes the hydrolysis ofthe terminal glucose moiety of amygdalin and clearly differentiated this enzyme from previously known mammalian /B-glucosidases. The enzyme was unable to hydrolyze gentiobiose, the disaccharide component of amygdalin, suggesting a requirement for an aryl or alkyl aglycone residue for enzymatic activity. The natural occurrence ofthis enzyme was unusual, being particularly plentiful in feline kidney but also present in rat and rabbit kidney and rodent intestine. It was notably absent in human kidney preparations. This enzyme and the subsequent activity of a (1-4)-glucosidase on the prunasin produced by the ((1-*6)-glucosidase were considered to be important in the metabolism of exogenous amygdalin because mandelonitrile can spontaneously release cyanide in vivo. Thus, it was suggested that, if amygdalin exerts a tumoricidal effect by release of cyanide, a tissue susceptible to amygdalin should contain the required (-glucosidases. In order to better characterize the occurrence of amygdalin and prunasin glucosidases, we have extended the previous study (13) to an examination of tissues from germ-free rats and normal and neoplastic human tissues.
MATERIALS AND METHODS
Amygdalin was obtained from Aldrich. Prunasin was prepared as described (13) . Gentiobiose was purchased from Sigma.
Germ-free male rats (200 g) were obtained from Charles River Breeding Laboratories, Wilmington, MA. Upon arrival, the rats were sacrificed by asphyxiation with solid C02; the tissues were removed and homogenized by hand in 10 vol ofcold distilled water. The mixtures were centrifuged at 500 X g for 10 min, and the supernatant suspensions were assayed for enzyme activity. The quantity of glucose enzymatically released from amygdalin, prunasin, and gentiobiose was determined with glucose oxidase reagent (Sigma) as described (13) . 3Glu-cosidase activity was also measured with 4-methylumbelliferyl-,B-D-glycopyranoside (Sigma) as substrate at pH 4.5 in acetate buffer and at pH 7.5 in phosphate buffer (14) . Glucocerebrosidase activity was also determined in the tissue specimens by using ['4C]glucocerebroside as described (15) . Protein was determined by the procedure of Lowry et at (16) .
Human tissues from 19 patients were obtained at operation from the Department of Pathology, Suburban Hospital, Bethesda, MD. Patients were unselected. The tissues were refrigerated until homogenization 2-16 hr postoperatively. Tissues were processed in the same manner as before, and the tissue diagnosis on each specimen was subsequently confirmed microscopically. Two specimens of human small intestine were obtained at autopsy. Postmortem diagnosis for each patient was cardiac disease, and no gross pathology was seen in the abdomen. The autopsies were performed the day after death, and the bodies had been refrigerated for an unstated time before autopsy.
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RESULTS
Enzymes that catalyze the cleavage of glucose from amygdalin and prunasin were present in the small intestine and intestinal contents of germ-free rats and in the kidney (Table 1) . These (3glucosidases were practically absent in the stomach and in the large intestine. Both proximal and distal halves of the small intestine mucosa contained both amygdalin-and prunasin-cleaving activity. The colon contents showed significant activity "downstream" from the site of high small intestinal mucosal activity. This observation is consistent with shedding ofmucosal elements or secretion ofthese enzymes, or both, into the lumen of the small intestine. The possibility of a bacterial source of these enzymes is remote because the rats were germ-free. The data obtained with human tissue confirm the localization of these 13-glucosidases to the small intestine ( sibly enzymatically liberated (22) , we are unable to substantiate However, we found no evidence in the more common tumors this rationale for the use of amygdalin (or prunasin) as a cancer (colon, breast, lung) to support the contention that amygdalin chemotherapeutic agent.
or prunasin would be expected to exert a therapeutic effect. A theoretical limitation of the present study was its reliance on surgical pathology specimens from a general hospital. SpeNote Added in Proof. Since submission of this manuscript, we had an cifically, during the period of this investigation, no small intesopportunity to examine P-glucosidase activity in a papillary carcinoma tinal tumors were obtained. It is possible that neoplasms ofthis of human kidney. Although there was significant hydrolysis of glucoorgan might be suitable targets for amygdalin (or prunasin).
cerebroside and 4-methyl-p-D-glucopyranoside, neither amygdalin nor
